Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
Content creator Jack Joseph has revealed how taking SARMs as a teenager led to liver failure, highlighting the risks of ...
Best SARM for muscle growth and strength for 2026 from leading supplement company CrazyBulk - which SARMS stack is best for bulking cycles and faster recovery' ...
Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...
As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...
A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...
Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...
PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
The FDA has granted traditional approval to Rubraca (rucaparib) for metastatic castration-resistant prostate cancer.
Clascoterone 5% topical solution, an anti-androgen that targets the hair follicle androgen receptor without measurable ...
Genetics play a role in low testosterone for some men, but underlying causes vary widely. Many genes influence testosterone ...
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback